Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2132PDF: 1696HTML: 378 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2883PDF: 1361HTML: 3569Untitled: 192Untitled: 204Untitled: 177 -
PROLIFERATION AND APOPTOSIS OF B-CELL LYMPHOMA CELLS UNDER TARGETED REGULATION OF FOXO3 BY miR-155 miR-155, FOXO3, B-cell lymphoma, proliferation, apoptosis, clinical characteristics
772PDF: 90HTML: 141 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
481PDF: 245HTML: 79 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1045PDF: 1159Suppl. Files: 569HTML: 88 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1194PDF: 1070HTML: 203 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1378HTML: 435PDF: 822 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3774PDF: 1662HTML: 11596Figures Haase: 199 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
1964PDF: 713HTML: 684Table1: patient's characteristics: 156Table 2: profile of each patient: 178 -
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3318PDF: 1966HTML: 7473 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2458HTML: 271PDF: 872 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2585PDF: 800HTML: 5214 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9074PDF: 6061HTML: 87959Fig.1b: 185Fig.1c: 190Fig.2a: 177Fig.2b: 176Fig.4: 188Fig.2c: 185Fig.3: 182Tab.1: 228Tab.2: 207Tab.3: 189Tab.4: 221Fig1a: 186 -
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3534PDF: 1181HTML: 4998Incidence age-standardized rates for HL across the Mediterranean basin: 203 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3257PDF: 1709HTML: 1086 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3554PDF: 2417HTML: 1467 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3589PDF: 886HTML: 6711 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1533PDF: 944HTML: 223 -
SOLITARY PLASMACYTOMA
3859PDF: 2175HTML: 1223fIGURES 1,2: 214 -
HEPARIN-BINDING PROTEIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INFECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Heparin-binding protein in adult patients
2277PDF: 998HTML: 148Suppl. Files: 512 -
TYROSINE KINASE INHIBITORS AND PREGNANCY
3573PDF: 1639HTML: 2674 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2171PDF: 1588HTML: 286 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3059PDF: 877HTML: 7164Kost Fig1: 183Kost Fig 2: 179Kost Fig3: 176Kost Fig 4: 190Kost Fig5: 185Kost fig 6: 173 -
-
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2453PDF: 785HTML: 1736 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
3942PDF: 1505HTML: 9188Untitled: 278Untitled: 184Untitled: 169Untitled: 164Untitled: 181Untitled: 339 -
-
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2766PDF: 1121HTML: 3283 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
3995PDF: 1053HTML: 3592Untitled: 177Cneo. Fig.1: 114Untitled: 105Untitled: 126Untitled: 133 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2803PDF: 1009HTML: 5520







